Granules India announced that the US Food & Drug Administration (USFDA) has approved its Abbreviated New Drug Application (ANDA) for Loperamide
Hydrochloride and Simethicone Tablets, 2 mg/125 mg (OTC). It is bioequivalent to the reference listed drug product, Imodium Multi-Symptom Relief Tablets, 2 mg/125 mg, of Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division.
Loperamide Hydrochloride and Simethicone Tablets are indicated to relieve symptoms of diarrhea plus bloating, pressure and cramps, commonly referred to as gas.
Granules now have a total of 52 ANDA approvals from US FDA (50 Final approvals and 2 tentative approvals).
The Imodium Multi-Symptom Relief ®️ brand and store brands had combined US sales of approximately $60 million MAT for the most recent twelve months.
Bazaarinformation team has many years of experience, covering the physical and future commodities markets with prominent commodity & equity trading advising which shines further with extensive network to get research from ground levels to generate proper reporting and movements. We are able to get evens out of odds in volatile markets and stockings. ...
